Literature DB >> 29982644

Recombinant human soluble thrombomodulin attenuates anti-glomerular basement membrane glomerulonephritis in Wistar-Kyoto rats through anti-inflammatory effects.

Shohei Tachibana1, Masayuki Iyoda1, Kei Matsumoto1, Yukihiro Wada1, Taihei Suzuki1, Ken Iseri1, Nobuhiro Kanazawa1, Takanori Shibata1.   

Abstract

BACKGROUND: Since recombinant human soluble thrombomodulin (RH-TM) has anti-inflammatory properties through neutralizing high-mobility group box 1 protein (HMGB1), the protective effects of RH-TM were examined in anti-glomerular basement membrane (GBM) glomerulonephritis (GN) in Wistar-Kyoto rats.
METHODS: Rats were injected with nephrotoxic serum (NTS) to induce anti-GBM GN on Day 0, and were given either RH-TM or vehicle from Day 0 to Day 6. Rats were sacrificed 7 days after NTS injection.
RESULTS: RH-TM-treated rats had decreased proteinuria and serum creatinine level. RH-TM significantly reduced the percentage of glomeruli with crescentic features and fibrinoid necrosis. In addition, RH-TM-treated rats had significantly reduced glomerular ED1+ macrophage accumulation as well as reduced renal cortical proinflammatory cytokine expression. Furthermore, RH-TM had a potent effect in reducing intercellular adhesion molecule-1 (ICAM-1) expression in kidneys and urine. RH-TM significantly reduced renal cortical mRNA levels for toll-like receptor -2 and -4, known as receptors for HMGB1, and their downstream adopter protein, myeloid differentiation primary respond protein 88 (MyD88).
CONCLUSIONS: We showed for the first time that anti-inflammatory effects, which were characterized by reduced glomerular macrophage influx concomitant with a marked reduction in proinflammatory cytokines, were involved in the mechanism of attenuating experimental anti-GBM GN by RH-TM. The observed effects might be attributable to the downregulation of ICAM-1 by reducing the HMGB1/TLR/MyD88 signaling pathway.
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  HMGB1; ICAM-1; anti-GBM glomerulonephritis; macrophages; thrombomodulin

Mesh:

Substances:

Year:  2019        PMID: 29982644     DOI: 10.1093/ndt/gfy201

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

Review 1.  Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential.

Authors:  Takashi Ito; Jecko Thachil; Hidesaku Asakura; Jerrold H Levy; Toshiaki Iba
Journal:  Crit Care       Date:  2019-08-15       Impact factor: 9.097

2.  Thrombomodulin is upregulated in the kidneys of women with pre-eclampsia.

Authors:  Cleo C L van Aanhold; Manon Bos; Katrina M Mirabito Colafella; Marie-Louise P van der Hoorn; Ron Wolterbeek; Jan A Bruijn; Kitty W M Bloemenkamp; Anton H van den Meiracker; A H Jan Danser; Hans J Baelde
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

3.  Reno-protective effect of IL-34 inhibition on cisplatin-induced nephrotoxicity in mice.

Authors:  Yukihiro Wada; Masayuki Iyoda; Kei Matsumoto; Taihei Suzuki; Shohei Tachibana; Nobuhiro Kanazawa; Hirokazu Honda
Journal:  PLoS One       Date:  2021-01-11       Impact factor: 3.240

Review 4.  Thrombomodulin as a Physiological Modulator of Intravascular Injury.

Authors:  Kanako Watanabe-Kusunoki; Daigo Nakazawa; Akihiro Ishizu; Tatsuya Atsumi
Journal:  Front Immunol       Date:  2020-09-16       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.